Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17945
Corporate User License Price USD 750
Corporate User License Price INR 53835
Site License Price USD 500
Site License Price INR 35890
Request a Quote

Report Title

BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile



Executive Summary

Summary

BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company's aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

BioTime Inc, Medical Equipment, Deal Details 12

Partnerships 12

OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12

OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13

OncoCyte Expands Co-Development Agreement with Wistar Institute 14

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15

OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16

Equity Offering 18

OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18

OncoCyte Raises USD10 Million in Private Placement of Shares 19

BioTime Completes Public Offering of Shares for USD28.8 Million 20

OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22

OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24

BioTime to Raise up to USD25 Million in Private Placement of Shares 26

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27

OncoCyte Raises USD3.2 Million in Private Placement of Units 28

OncoCyte Raises USD7.3 Million in Private Placement of Units 29

BioTime Raises USD5 Million in Private Placement of Shares 30

BioTime Raises USD20.4 Million in Private Placement of Shares 31

OncoCyte Raises USD3.3 Million in Private Placement of Shares 33

BioTime Completes Private Placement Of Shares For USD 6.4 Million 34

BioTime Announces Public Offering Of Shares For Up To USD 15 Million 35

BioTime Completes Public Offering Of Shares For USD 3.5 Million 36

BioTime Completes Private Placement Of Units For USD 9 Million 37

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 38

BioTime Announces Private Placement Of Common Stock 40

Acquisition 41

BioIVT Acquires Ascendance Biotech 41

BioTime Inc-Key Competitors 42

BioTime Inc-Key Employees 43

BioTime Inc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Joint Venture 45

Recent Developments 46

Financial Announcements 46

Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 46

May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 48

Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 50

Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 52

Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 54

May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 56

Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 58

Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 61

Corporate Communications 62

Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 62

Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 63

Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 64

Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 65

Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66

Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67

Product News 68

Aug 16, 2018: BioTime to present data at the Military Health System Research Symposium 68

May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69

Other Significant Developments 70

Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

BioTime Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

List of Tables

BioTime Inc, Medical Equipment, Key Facts, 2017 2

BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

BioTime Inc, Deals By Market, 2012 to YTD 2018 9

BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12

OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13

OncoCyte Expands Co-Development Agreement with Wistar Institute 14

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15

OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16

OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18

OncoCyte Raises USD10 Million in Private Placement of Shares 19

BioTime Completes Public Offering of Shares for USD28.8 Million 20

OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22

OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24

BioTime to Raise up to USD25 Million in Private Placement of Shares 26

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27

OncoCyte Raises USD3.2 Million in Private Placement of Units 28

OncoCyte Raises USD7.3 Million in Private Placement of Units 29

BioTime Raises USD5 Million in Private Placement of Shares 30

BioTime Raises USD20.4 Million in Private Placement of Shares 31

OncoCyte Raises USD3.3 Million in Private Placement of Shares 33

BioTime Completes Private Placement Of Shares For USD 6.4 Million 34

BioTime Announces Public Offering Of Shares For Up To USD 15 Million 35

BioTime Completes Public Offering Of Shares For USD 3.5 Million 36

BioTime Completes Private Placement Of Units For USD 9 Million 37

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 38

BioTime Announces Private Placement Of Common Stock 40

BioIVT Acquires Ascendance Biotech 41

BioTime Inc, Key Competitors 42

BioTime Inc, Key Employees 43

BioTime Inc, Subsidiaries 44

BioTime Inc, Joint Venture 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

BioTime Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand